BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 27789529)

  • 1. Molecular Pathways: The eIF4F Translation Initiation Complex-New Opportunities for Cancer Treatment.
    Malka-Mahieu H; Newman M; Désaubry L; Robert C; Vagner S
    Clin Cancer Res; 2017 Jan; 23(1):21-25. PubMed ID: 27789529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the eIF4F translation initiation complex: a critical nexus for cancer development.
    Pelletier J; Graff J; Ruggero D; Sonenberg N
    Cancer Res; 2015 Jan; 75(2):250-63. PubMed ID: 25593033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired Tamoxifen Resistance in MCF-7 Breast Cancer Cells Requires Hyperactivation of eIF4F-Mediated Translation.
    Fagan DH; Fettig LM; Avdulov S; Beckwith H; Peterson MS; Ho YY; Wang F; Polunovsky VA; Yee D
    Horm Cancer; 2017 Aug; 8(4):219-229. PubMed ID: 28577281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translational control of cell fate: from integration of environmental signals to breaching anticancer defense.
    Bitterman PB; Polunovsky VA
    Cell Cycle; 2012 Mar; 11(6):1097-107. PubMed ID: 22356766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attacking a nexus of the oncogenic circuitry by reversing aberrant eIF4F-mediated translation.
    Bitterman PB; Polunovsky VA
    Mol Cancer Ther; 2012 May; 11(5):1051-61. PubMed ID: 22572598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer.
    Garrido MF; Martin NJ; Bertrand M; Gaudin C; Commo F; El Kalaany N; Al Nakouzi N; Fazli L; Del Nery E; Camonis J; Perez F; Lerondel S; Le Pape A; Compagno D; Gleave M; Loriot Y; Désaubry L; Vagner S; Fizazi K; Chauchereau A
    Clin Cancer Res; 2019 Jan; 25(2):710-723. PubMed ID: 30322877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.
    Demosthenous C; Han JJ; Stenson MJ; Maurer MJ; Wellik LE; Link B; Hege K; Dogan A; Sotomayor E; Witzig T; Gupta M
    Oncotarget; 2015 Apr; 6(11):9488-501. PubMed ID: 25839159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the eIF4F translation initiation complex for cancer therapy.
    Konicek BW; Dumstorf CA; Graff JR
    Cell Cycle; 2008 Aug; 7(16):2466-71. PubMed ID: 18719377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of small molecules targeting eIF4A.
    Naineni SK; Itoua Maïga R; Cencic R; Putnam AA; Amador LA; Rodriguez AD; Jankowsky E; Pelletier J
    RNA; 2020 May; 26(5):541-549. PubMed ID: 32014999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing anti-neoplastic biotherapeutics against eIF4F.
    Steinberger J; Chu J; Maïga RI; Sleiman K; Pelletier J
    Cell Mol Life Sci; 2017 May; 74(9):1681-1692. PubMed ID: 28004147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the translation machinery in cancer.
    Bhat M; Robichaud N; Hulea L; Sonenberg N; Pelletier J; Topisirovic I
    Nat Rev Drug Discov; 2015 Apr; 14(4):261-78. PubMed ID: 25743081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging therapeutics targeting mRNA translation.
    Malina A; Mills JR; Pelletier J
    Cold Spring Harb Perspect Biol; 2012 Apr; 4(4):a012377. PubMed ID: 22474009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-Myc and eIF4F constitute a feedforward loop that regulates cell growth: implications for anticancer therapy.
    Lin CJ; Malina A; Pelletier J
    Cancer Res; 2009 Oct; 69(19):7491-4. PubMed ID: 19773439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTOR signaling: implications for cancer and anticancer therapy.
    Petroulakis E; Mamane Y; Le Bacquer O; Shahbazian D; Sonenberg N
    Br J Cancer; 2006 Jan; 94(2):195-9. PubMed ID: 16404421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
    Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
    Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor suppression by small molecule inhibitors of translation initiation.
    Chen L; Aktas BH; Wang Y; He X; Sahoo R; Zhang N; Denoyelle S; Kabha E; Yang H; Freedman RY; Supko JG; Chorev M; Wagner G; Halperin JA
    Oncotarget; 2012 Aug; 3(8):869-81. PubMed ID: 22935625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translating from cancer to the brain: regulation of protein synthesis by eIF4F.
    Kats IR; Klann E
    Learn Mem; 2019 Sep; 26(9):332-342. PubMed ID: 31416906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The proteasome inhibitor, MG132, promotes the reprogramming of translation in C2C12 myoblasts and facilitates the association of hsp25 with the eIF4F complex.
    Cowan JL; Morley SJ
    Eur J Biochem; 2004 Sep; 271(17):3596-611. PubMed ID: 15317596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer Plasticity: The Role of mRNA Translation.
    Lee LJ; Papadopoli D; Jewer M; Del Rincon S; Topisirovic I; Lawrence MG; Postovit LM
    Trends Cancer; 2021 Feb; 7(2):134-145. PubMed ID: 33067172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The plasticity of mRNA translation during cancer progression and therapy resistance.
    Fabbri L; Chakraborty A; Robert C; Vagner S
    Nat Rev Cancer; 2021 Sep; 21(9):558-577. PubMed ID: 34341537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.